Business article - March 6, 2019
Company in focus: Modus Therapeutics
Swedish drug development company Modus Therapeutics has had a busy year, and 2019 could take them one step closer to having sevuparin on the market. In 2016 the clinical-stage drug development and Karolinska Development portfolio company Dilaforette Holding changed its name to Modus Therapeutics Holding. The move signified the company’s emancipation from its parent company […]
Clinical Trials - March 6, 2019
First cohort dosed in Modus Therapeutics study
The first cohort has been successfully dosed in the Phase 1, single ascending dose study to explore the pharmacokinetics and safety and tolerability of subcutaneous sevuparin injections in healthy volunteers (HV). This study complements a large Phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. “This Phase 1 study […]
Clinical Trials - January 7, 2019
Modus Therapeutics completes enrollment of Phase II study
The company announces that it has completed patient enrollment in its multi-centre, Phase II, randomized, double-blind, placebo-controlled study to explore the efficacy and safety of Sevuparin infusion for the management of Acute Vaso-Occlusive Crisis (VOC) in patients with sickle cell disease. This large, expanded, global Phase II study recruited over 140 patients at clinical sites across […]
